Full-Time

Mechanistic Biologist

Confirmed live in the last 24 hours

Retro Biosciences

Retro Biosciences

51-200 employees

Develops therapeutics targeting aging mechanisms

Compensation Overview

$130k - $160k/yr

Mid, Senior

San Carlos, CA, USA

In Person

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • 3–7 years of post-PhD or equivalent experience in assay development, cell biology, or neurodegeneration in a biotech or academic setting
  • Experienced in developing cell-based assays to measure autophagy, lysosomal function, protein degradation, or aggregate clearance
  • Exposure to early translational research, including biomarker development or patient-derived systems, or omics technologies (e.g., transcriptomics, proteomics, metabolomics)
  • Fluent in techniques such as high-content imaging, flow cytometry, biochemical reporter assays, or live-cell readouts, or chemoproteomics approaches for target engagement and pathway analysis
  • Excellent communicator who thrives in highly collaborative, interdisciplinary environments
  • Energized by fast-paced, mission-driven work and take pride in building systems that others can rely on
Responsibilities
  • Develop and optimize cellular and biochemical assays to measure autophagic flux, lysosomal function, and aggregate clearance, with the ability to integrate omics approaches such as proteomics and transcriptomics for mechanistic insight
  • Develop and optimize robust, quantitative assay systems for Structure-Activity Relationship (SAR) and compound screening
  • Drive target validation and mechanism-of-action studies through customized assay systems
  • Generate mechanistic, target engagement, and omics data to inform regulatory filings and support clinical development activities
  • Collaborate with internal and external partners to ensure assay relevance, reproducibility, and translational value
  • Maintain high standards of data integrity, documentation, and scientific communication
Desired Qualifications
  • Worked with neurodegenerative disease models, iPSC-derived neurons, or lysosomal storage diseases
  • Experience supporting IND-enabling studies or clinical candidate selection
  • Familiar with chemical biology or SAR-guided screening
  • Exposure to omics platforms like Olink, SomaLogic, or mass spectrometry and experience applying omics to neurodegenerative disease models

Retro Biosciences focuses on extending healthy human lifespan by ten years through the development of therapeutics that target the cellular mechanisms of aging. The company addresses the root causes of age-related diseases, which are responsible for a significant portion of healthcare costs in the U.S. Retro Biosciences operates three main programs: cellular reprogramming, plasma-inspired therapeutics, and autophagy, each at different stages of development. They utilize advanced technologies like single-cell multi-omics and computational biology to support their research. Unlike many competitors, Retro Biosciences aims to prevent multiple diseases rather than just treating them, positioning itself uniquely in the biotech field. The company's goal is to reduce healthcare costs associated with aging and improve overall health outcomes by successfully developing and commercializing its therapeutic candidates.

Company Size

51-200

Company Stage

Early VC

Total Funding

$180M

Headquarters

Redwood City, California

Founded

2021

Simplify Jobs

Simplify's Take

What believers are saying

  • Retro Biosciences secured $1 billion in funding to support its longevity mission.
  • Partnerships with MCRI and Multiply Labs enhance therapeutic development and manufacturing capabilities.
  • Growing interest in personalized medicine aligns with Retro's focus on autologous cell therapies.

What critics are saying

  • Intensifying competition in the longevity biotech sector may impact funding and partnerships.
  • Public and regulatory scrutiny of anti-aging therapies could lead to stricter regulations.
  • Reliance on large funding rounds poses financial risks if market conditions change.

What makes Retro Biosciences unique

  • Retro Biosciences focuses on cellular reprogramming, autophagy, and plasma-inspired therapeutics.
  • The company aims to extend healthy human lifespan by ten years.
  • Retro Biosciences employs advanced technologies like single-cell multi-omics and computational biology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Paid Holidays

Parental Leave

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

4%
News Medical
May 19th, 2025
New partnership aims to advance treatments for blood disorders and leukemia

MCRI, a flagship member of the Melbourne Biomedical Precinct and the Melbourne arm of the international research consortium, the Novo Nordisk Foundation Center for Stem Cell Medicine, reNEW, has today announced a significant research and commercial licensing agreement with Retro Biosciences.

Bioengineer
May 19th, 2025
New $35M US Partnership to Propel Breakthroughs in Blood Disorder Treatments

By integrating MCRI's cutting-edge discoveries with its proprietary platforms, Retro Biosciences aims to develop novel, autologous blood stem cell therapies that could eliminate the fatal risks associated with donor mismatches and immunological rejection.

Endpoints News
May 15th, 2025
Retro Biosciences Seeks $1B Funding

Retro Biosciences, a longevity startup, has partnered with the Murdoch Children’s Research Institute in Australia to develop personalized blood disorder therapies. The company, backed by Sam Altman, is seeking $1 billion in funding.

Fortune
Jan 24th, 2025
Retro Biosciences Secures $1B for Longevity

Sam Altman is backing Retro Biosciences with a new funding round of $1 billion to extend human lifespan.

HK Silicon
Jan 23rd, 2025
Retro Biosciences to Raise $1B Funding

Retro Biosciences, a biotech company backed by OpenAI CEO Sam Altman, plans to raise $1 billion to fund its project aimed at extending human lifespan by 10 years. Altman initially provided $180 million in seed funding and will contribute more in the Series A round.